A Phase 1 interventional study of BI 10773/linagliptin and BI 10773/linagliptin in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-03-19.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of the current study is to investigate the relative bioavailability of BI 10773 / linagliptin fixed dose combination tablet (formulation A1, Treatment A, Test) compared to BI 10773 given in free combination with linagliptin (Treatment B, Reference), both in the fasting state. All 42 subjects entered are planned to be included in this comparison.
The secondary objective is to investigate the relative bioavailability of BI 10773 / linagliptin fixed dose combination tablet after administration of a standardised high fat, high caloric meal (formulation A1, Treatment C, Test) compared to BI 10773 / linagliptin fixed dose combination in the fasting state (formulation A1,Treatment A, Reference). Of the 42 subjects entered 18 subjects are planned to be included in this comparison.
An additional objective is to investigate the relative bioavailability of a second formulation of the fixed dose combination tablet of BI 10773 / linagliptin (formulation A3,Treatment D, Test) compared to BI 10773 / linagliptin fixed dose combination tablet (formulation A1,Treatment A, Reference). Of the 42 subjects entered 24 subjects are planned to be included in this comparison.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion criteria:
healthy male and female subjects
medium single dose ofBI 10773/linagliptin FDC (Formulation A1)
Drug: BI 10773/linagliptin
medium single dose of mono components BI 10773/linagliptin
Drug: BI 10773/linagliptin SID
medium single dose of BI 10773/linagliptin FDC (Formulation A1) after high fat, high caloric meal
Drug: BI 10773/linagliptin FDC
medium single dose of BI 10773/linagliptin FDC (Formulation A3)
Drug: BI 10773/linagliptin
Drug pages: EmpagliflozinStudies of EmpagliflozinEmpagliflozin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · LinagliptinStudies of LinagliptinLinagliptin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
medium single dose of BI 10773/linagliptin FDC (Formulation A1)
Drug pages: EmpagliflozinStudies of EmpagliflozinEmpagliflozin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · LinagliptinStudies of LinagliptinLinagliptin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
medium single dose of BI 10773/linagliptin FDC (Formulation A3)
medium single dose of mono components BI 10773/linagliptin
Drug pages: EmpagliflozinStudies of EmpagliflozinEmpagliflozin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · LinagliptinStudies of LinagliptinLinagliptin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
medium single dose of BI 10773/linagliptin FDC (Formulation A1) after high fat, high caloric meal
Empagliflozin: Area Under the Curve 0 to the Last Quantifiable Drug Plasma Concentration (AUC0-tz)
Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 to the last quantifiable drug plasma concentration. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.
Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration
Linagliptin: Area Under the Curve 0 to 72 Hours (AUC0-72)
Area under the concentration-time curve of linagliptin in plasma over the time interval from 0 to 72 hours. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.
Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration
Empagliflozin: Maximum Measured Concentration (Cmax)
Maximum measured concentration of empagliflozin (empa) in plasma. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.
Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration
Linagliptin: Maximum Measured Concentration (Cmax)
Maximum measured concentration of linagliptin in plasma. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.
Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration
Empagliflozin Fed vs Fasted: Maximum Measured Concentration (Cmax)
Maximum measured concentration of empagliflozin (empa) in plasma, comparing fed with fasted. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.
Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration
Empagliflozin Fed vs Fasted: Area Under the Curve 0 to the Last Quantifiable Drug Plasma Concentration (AUC0-tz)
Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 to the last quantifiable drug plasma concentration. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.
Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration
Linagliptin Fed vs Fasted: Maximum Measured Concentration (Cmax)
Maximum measured concentration of linagliptin in plasma. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.
Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration
Linagliptin Fed vs Fasted: Area Under the Curve 0 to 72 Hours (AUC0-72)
Area under the concentration-time curve of linagliptin in plasma over the time interval from 0 to 72 hours. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.
Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration
Empagliflozin Formulation Comparison: Maximum Measured Concentration (Cmax)
Maximum measured concentration of empagliflozin (empa) in plasma. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.
Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration
Empagliflozin Formulation Comparison: Area Under the Curve 0 to the Last Quantifiable Drug Plasma Concentration (AUC0-tz)
Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 to the last quantifiable drug plasma concentration. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.
Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration
Linagliptin Formulation Comparison: Maximum Measured Concentration (Cmax)
Maximum measured concentration of linagliptin in plasma. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.
Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration
Linagliptin Formulation Comparison: Area Under the Curve 0 to 72 Hours (AUC0-72)
Area under the concentration-time curve of linagliptin in plasma over the time interval from 0 to 72 hours. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.
Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration
Empagliflozin: Time From Last Dosing to Maximum Measured Concentration (Tmax)
Time from last dosing to the maximum measured concentration of empagliflozin (empa) in plasma.
Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration
Linagliptin: Time From Last Dosing to Maximum Measured Concentration (Tmax)
Time from last dosing to the maximum measured concentration of linagliptin in plasma
Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration
Empagliflozin: Area Under the Curve 0 to Infinity (AUC0-∞)
Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 extrapolated to infinity. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.
Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration
Linagliptin: Area Under the Curve 0 to Infinity (AUC0-∞)
Area under the concentration-time curve of linagliptin in plasma over the time interval from 0 extrapolated to infinity. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.
Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration
Empagliflozin Fed vs Fasted: Area Under the Curve 0 to Infinity (AUC0-∞)
Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 extrapolated to infinity. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.
Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration
Linagliptin Fed vs Fasted: Area Under the Curve 0 to Infinity (AUC0-∞)
Area under the concentration-time curve of linagliptin in plasma over the time interval from 0 extrapolated to infinity. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.
Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration
Empagliflozin Formulation Comparison: Area Under the Curve 0 to Infinity (AUC0-∞)
Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 extrapolated to infinity. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.
Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration
Linagliptin Formulation Comparison: Area Under the Curve 0 to Infinity (AUC0-∞)
Area under the concentration-time curve of linagliptin in plasma over the time interval from 0 extrapolated to infinity. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.
Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration
Clinically Relevant Abnormalities for Physical Examination, Vital Signs, ECG, Blood Chemistry and Assessment of Tolerability by the Investigator
Clinically Relevant Abnormalities for Physical Examination, Vital Signs, ECG, Blood Chemistry and Assessment of Tolerability by the Investigator. New abnormal findings or worsening of baseline conditions were reported as Adverse Events. Time frame for adverse event was until the end-of-study examination.
Time frame: Drug administration until next treatment period/end-of-study examination, up to 36 days
| Milestone | Study Overall |
|---|---|
| Started | 42 |
| Received empa/linagliptin fdc a1(fasted) | 42 |
| Rec. empa/linagliptin ind.tablet(fasted) | 41 |
| Received empa/linagliptin fdc a1 (fed) | 18 |
| Received empa/linagliptin fdc a3(fasted) | 24 |
| Completed | 41 |
| Not completed | 1 |
| Withdrew: Adverse event | 1 |
Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 to the last quantifiable drug plasma concentration. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.
| nmol*h/L | Empa Plus Linagliptin FDC A1 (Fasted) | Empa Plus Linagliptin Individual Tablets (Fasted) |
|---|---|---|
| Empagliflozin: Area Under the Curve 0 to the Last Quantifiable Drug Plasma Concentration (AUC0-tz) | 5990 ± 21.0 | 5720 ± 20.8 |
Area under the concentration-time curve of linagliptin in plasma over the time interval from 0 to 72 hours. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.
| nmol*h/L | Empa Plus Linagliptin FDC A1 (Fasted) | Empa Plus Linagliptin Individual Tablets (Fasted) |
|---|---|---|
| Linagliptin: Area Under the Curve 0 to 72 Hours (AUC0-72) | 264 ± 22.1 | 250 ± 22.1 |
Maximum measured concentration of empagliflozin (empa) in plasma. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.
| nmol/L | Empa Plus Linagliptin FDC A1 (Fasted) | Empa Plus Linagliptin Individual Tablets (Fasted) |
|---|---|---|
| Empagliflozin: Maximum Measured Concentration (Cmax) | 862 ± 26.8 | 803 ± 24.9 |
Maximum measured concentration of linagliptin in plasma. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.
| nmol/L | Empa Plus Linagliptin FDC A1 (Fasted) | Empa Plus Linagliptin Individual Tablets (Fasted) |
|---|---|---|
| Linagliptin: Maximum Measured Concentration (Cmax) | 8.19 ± 36.4 | 7.49 ± 31.0 |
Time from last dosing to the maximum measured concentration of empagliflozin (empa) in plasma.
| hours | Empa Plus Linagliptin FDC A1 (Fasted) | Empa Plus Linagliptin Individual Tablets (Fasted) | Empa Plus Linagliptin FDC A1 (Fed) | Empa Plus Linagliptin FDC A3 (Fasted) |
|---|---|---|---|---|
| Empagliflozin: Time From Last Dosing to Maximum Measured Concentration (Tmax) | 1.50 (0.67 to 4.00) | 1.25 (0.67 to 3.98) | 2.00 (0.67 to 4.00) | 1.50 (0.67 to 3.00) |
Time from last dosing to the maximum measured concentration of linagliptin in plasma
| hours | Empa Plus Linagliptin FDC A1 (Fasted) | Empa Plus Linagliptin Individual Tablets (Fasted) | Empa Plus Linagliptin FDC A1 (Fed) | Empa Plus Linagliptin FDC A3 (Fasted) |
|---|---|---|---|---|
| Linagliptin: Time From Last Dosing to Maximum Measured Concentration (Tmax) | 1.50 (0.33 to 6.03) | 1.75 (0.67 to 10.0) | 2.25 (1.00 to 4.00) | 1.50 (0.33 to 4.00) |
Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 extrapolated to infinity. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.
| nmol*h/L | Empa Plus Linagliptin FDC A1 (Fasted) | Empa Plus Linagliptin Individual Tablets (Fasted) |
|---|---|---|
| Empagliflozin: Area Under the Curve 0 to Infinity (AUC0-∞) | 6060 ± 20.7 | 5800 ± 20.9 |
Area under the concentration-time curve of linagliptin in plasma over the time interval from 0 extrapolated to infinity. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.
| nmol*h/L | Empa Plus Linagliptin FDC A1 (Fasted) | Empa Plus Linagliptin Individual Tablets (Fasted) |
|---|---|---|
| Linagliptin: Area Under the Curve 0 to Infinity (AUC0-∞) | 435 ± 26.5 | 410 ± 29.8 |
Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 extrapolated to infinity. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.
| nmol*h/L | Empa Plus Linagliptin FDC A1 (Fasted) | Empa Plus Linagliptin FDC A1 (Fed) |
|---|---|---|
| Empagliflozin Fed vs Fasted: Area Under the Curve 0 to Infinity (AUC0-∞) | 6410 ± 16.0 | 5500 ± 16.8 |
Maximum measured concentration of empagliflozin (empa) in plasma, comparing fed with fasted. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.
| nmol/L | Empa Plus Linagliptin FDC A1 (Fasted) | Empa Plus Linagliptin FDC A1 (Fed) |
|---|---|---|
| Empagliflozin Fed vs Fasted: Maximum Measured Concentration (Cmax) | 949 ± 23.7 | 583 ± 21.7 |
Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 to the last quantifiable drug plasma concentration. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.
| nmol*h/L | Empa Plus Linagliptin FDC A1 (Fasted) | Empa Plus Linagliptin FDC A1 (Fed) |
|---|---|---|
| Empagliflozin Fed vs Fasted: Area Under the Curve 0 to the Last Quantifiable Drug Plasma Concentration (AUC0-tz) | 6330 ± 16.4 | 5400 ± 16.3 |
Area under the concentration-time curve of linagliptin in plasma over the time interval from 0 extrapolated to infinity. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.
| nmol*h/L | Empa Plus Linagliptin FDC A1 (Fasted) | Empa Plus Linagliptin FDC A1 (Fed) |
|---|---|---|
| Linagliptin Fed vs Fasted: Area Under the Curve 0 to Infinity (AUC0-∞) | 453 ± 24.2 | 421 ± 19.0 |
Maximum measured concentration of linagliptin in plasma. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.
| nmol/L | Empa Plus Linagliptin FDC A1 (Fasted) | Empa Plus Linagliptin FDC A1 (Fed) |
|---|---|---|
| Linagliptin Fed vs Fasted: Maximum Measured Concentration (Cmax) | 8.97 ± 40.0 | 6.14 ± 17.0 |
Area under the concentration-time curve of linagliptin in plasma over the time interval from 0 to 72 hours. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.
| nmol*h/L | Empa Plus Linagliptin FDC A1 (Fasted) | Empa Plus Linagliptin FDC A1 (Fed) |
|---|---|---|
| Linagliptin Fed vs Fasted: Area Under the Curve 0 to 72 Hours (AUC0-72) | 275 ± 21.7 | 250 ± 19.2 |
Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 extrapolated to infinity. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.
| nmol*h/L | Empa Plus Linagliptin FDC A1 (Fasted) | Empa Plus Linagliptin FDC A3 (Fasted) |
|---|---|---|
| Empagliflozin Formulation Comparison: Area Under the Curve 0 to Infinity (AUC0-∞) | 5810 ± 23.1 | 5560 ± 20.8 |
Maximum measured concentration of empagliflozin (empa) in plasma. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.
| nmol/L | Empa Plus Linagliptin FDC A1 (Fasted) | Empa Plus Linagliptin FDC A3 (Fasted) |
|---|---|---|
| Empagliflozin Formulation Comparison: Maximum Measured Concentration (Cmax) | 802 ± 27.0 | 787 ± 25.2 |
Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 to the last quantifiable drug plasma concentration. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.
| nmol*h/L | Empa Plus Linagliptin FDC A1 (Fasted) | Empa Plus Linagliptin FDC A3 (Fasted) |
|---|---|---|
| Empagliflozin Formulation Comparison: Area Under the Curve 0 to the Last Quantifiable Drug Plasma Concentration (AUC0-tz) | 5740 ± 23.3 | 5490 ± 21.1 |
Area under the concentration-time curve of linagliptin in plasma over the time interval from 0 extrapolated to infinity. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.
| nmol*h/L | Empa Plus Linagliptin FDC A1 (Fasted) | Empa Plus Linagliptin FDC A3 (Fasted) |
|---|---|---|
| Linagliptin Formulation Comparison: Area Under the Curve 0 to Infinity (AUC0-∞) | 423 ± 28.3 | 393 ± 33.8 |
Maximum measured concentration of linagliptin in plasma. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.
| nmol/L | Empa Plus Linagliptin FDC A1 (Fasted) | Empa Plus Linagliptin FDC A3 (Fasted) |
|---|---|---|
| Linagliptin Formulation Comparison: Maximum Measured Concentration (Cmax) | 7.65 ± 32.7 | 7.93 ± 33.5 |
Area under the concentration-time curve of linagliptin in plasma over the time interval from 0 to 72 hours. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.
| nmol*h/L | Empa Plus Linagliptin FDC A1 (Fasted) | Empa Plus Linagliptin FDC A3 (Fasted) |
|---|---|---|
| Linagliptin Formulation Comparison: Area Under the Curve 0 to 72 Hours (AUC0-72) | 256 ± 22.4 | 247 ± 26.3 |
Clinically Relevant Abnormalities for Physical Examination, Vital Signs, ECG, Blood Chemistry and Assessment of Tolerability by the Investigator. New abnormal findings or worsening of baseline conditions were reported as Adverse Events. Time frame for adverse event was until the end-of-study examination.
| participants | Empa Plus Linagliptin FDC A1 (Fasted) | Empa Plus Linagliptin Indivdual Tablets (Fasted) | Empa Plus Linagliptin FDC A1 (Fed) | Empa Plus Linagliptin FDC A3 (Fasted) |
|---|---|---|---|---|
| Clinically Relevant Abnormalities for Physical Examination, Vital Signs, ECG, Blood Chemistry and Assessment of Tolerability by the Investigator | 0 | 0 | 0 | 0 |
Collected over Treatment period and following washout period, up to 36 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Empa Plus Linagliptin FDC A1 (Fasted) | — | 0/42 (0%) | 8/42 (19%) |
| Empa Plus Linagliptin Individual Tablets (Fasted) | — | 0/41 (0%) | 5/41 (12.2%) |
| Empa Plus Linagliptin FDC A1 (Fed) | — | 0/18 (0%) | 6/18 (33.3%) |
| Empa Plus Linagliptin FDC A3 (Fasted) | — | 0/24 (0%) | 4/24 (16.7%) |
| Event | Empa Plus Linagliptin FDC A1 (Fasted) | Empa Plus Linagliptin Individual Tablets (Fasted) | Empa Plus Linagliptin FDC A1 (Fed) | Empa Plus Linagliptin FDC A3 (Fasted) |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 1/42 | 1/41 | 3/18 | 0/24 |
| HeadacheNervous system disorders | 4/42 | 4/41 | 1/18 | 2/24 |
| Abdominal painGastrointestinal disorders | 0/42 | 0/41 | 1/18 | 1/24 |
| NauseaGastrointestinal disorders | 2/42 | 0/41 | 1/18 | 1/24 |
| VomitingGastrointestinal disorders | 2/42 | 2/41 | 1/18 | 1/24 |
| Back painMusculoskeletal and connective tissue disorders | 1/42 | 0/41 | 1/18 | 0/24 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 0/42 | 0/41 | 1/18 | 0/24 |
| Age, Continuous(years) | Study Overall |
|---|---|
| Mean | 40.3 ± 10.3 |
| Sex: Female, Male(Participants) | Study Overall |
|---|---|
| Female | 25 |
| Male | 17 |
The record gives a start of Aug 2010 and a primary completion of Nov 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2015, 4 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Empagliflozin · Linagliptin